Nurix Therapeutics, Inc.
NRIX
Rank in Stocks
#6381
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses... Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Brutonโs tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Share Price
$16.14
Last synced: 2026-11-09
Market Cap
$1.76B
Change (1 day)
5.49%
Change (1 year)
25.51%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Nurix Therapeutics, Inc. (NRIX)
Category
Healthcare
EPS for Nurix Therapeutics, Inc. (NRIX)
EPS as of August 2026 TTM: $2.51
According to Nurix Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $2.51. At the end of 2025 the company had an EPS of $-3.05, a decrease compared to its 2024 EPS of $-2.88.
EPS history for Nurix Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $2.51 | -182.30% |
| 2025 | $-3.05 | 5.90% |
| 2024 | $-2.88 | 8.68% |
| 2023 | $-2.65 | -28.57% |
| 2022 | $-3.71 | 35.90% |
| 2021 | $-2.73 | -1.09% |
| 2020 | $-2.76 | 392.86% |
| 2019 | $-0.56 | -5.08% |
| 2018 | $-0.59 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 523.90% |
US
|
|
| $-7.07 | -381.67% |
US
|
|
| $-5.29 | -310.76% |
AU
|
|
| $12.88 | 413.15% |
BE
|
|
| $21.56 | 758.96% |
NL
|
Questions about Nurix Therapeutics, Inc.'s earnings per share (EPS)
What is Nurix Therapeutics, Inc.'s earnings per share (EPS)?
Nurix Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $2.51, as of Aug 2026.
What was Nurix Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Nurix Therapeutics, Inc.'s earnings per share (EPS) was $-3.05, compared with $-2.88 in 2024.
How has Nurix Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Nurix Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($-2.65) and lowest in 2022 ($-3.71).
How does Nurix Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Nurix Therapeutics, Inc.'s earnings per share (EPS) ($2.51) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.